Profile
Ralph Brandenberger formerly worked at Geron Corp., as Director-Process Sciences from 2001 to 2012, Neurona Therapeutics, Inc., as Senior Director-Process Development from 2016 to 2018, Baxalta US, Inc., as Head-Technical Operations from 2012 to 2016, and Nkarta, Inc., as Chief Technical Officer from 2022 to 2025.
Dr. Brandenberger received his graduate degree and doctorate degree from the University of Basel.
Former positions of Ralph Brandenberger
| Companies | Position | End |
|---|---|---|
| NKARTA, INC. | Chief Tech/Sci/R&D Officer | 01/03/2025 |
Neurona Therapeutics, Inc.
Neurona Therapeutics, Inc. BiotechnologyHealth Technology Develops cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases | Corporate Officer/Principal | 01/03/2018 |
Baxalta US, Inc.
Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Corporate Officer/Principal | 01/04/2016 |
| GERON CORPORATION | Corporate Officer/Principal | 01/06/2012 |
Training of Ralph Brandenberger
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Geron Corp.
Geron Corp. BiotechnologyHealth Technology Discovers and develops therapeutic products for cancer | Health Technology |
Neurona Therapeutics, Inc.
Neurona Therapeutics, Inc. BiotechnologyHealth Technology Develops cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases | Health Technology |
University of Basel
University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baxalta US, Inc.
Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Health Technology |
Nkarta, Inc.
Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
- Stock Market
- Insiders
- Ralph Brandenberger
















